Patrick Sabaria, a medical device pioneer who helped establish the intraocular lens and the coronary stent in Europe, passed away unexpectedly last month. Sabaria was 61.
Stents
Stent wars: Shrinkage concerns resurface in Medtronic/Boston Scientific DES trial
Cordis releases 2-year data from Incraft stent trial
Cordis Corp, a Johnson & Johnson (NYSE:JNJ) subsidiary, released 2-year data from its INNOVATION trial testing the safety and performance of the Incraft abdominal aortic aneurysm stent graft system.
Medtronic lands expanded FDA approval for Valiant Captivia
Cordis S.M.A.R.T. stent still looking good at 3 years
Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. reported another year of results from its STROLL trial, which studied the durability and performance of the company’s S.M.A.R.T. vascular stent.
U.K. stent biomaterials project lands $8M grant
The ReBioStent project, led by U.K.-based Ceram, landed a $8 million (€5.8 million) grant to put towards developing new biomaterials and new arterial stents.
The ReBioStent project is seeking to develop biodegradable and biocompatible medical products, including stents. The 3-year project began this year and currently has 14 academy and industry partners working on it, according to a press release.
AqueSys raises $43.6M and closes U.S. trial of XEN Gel glaucoma stent
California ophthalmic devices maker AqueSys touted a couple of milestones today, landing a successful $43.6 million Series D funding round and closing enrollment in U.S. clinical trial of its XEN Gel stent for treatment of glaucoma.
The funding will allow AqueSys to make progress with its clinical trials, regulatory pursuits and commercialization efforts, president & CEO Ron Bache said in prepared remarks.
Medinol, Ariad Pharmaceuticals launch stent trials
Stentys expands in Asia with new distribution deals
Stentys SA (EPA:STNT) hopes to widen its footprint in Asia with the help of a few new distribution deals in the region.
Abbott settles stents class action for $5.5M
Xlumena wins FDA nod for Axios pancreatic stent
Xlumena won FDA approval to market its Axios stent and delivery system, landing approval through the FDA’s less-stringent de novo review pathway.
The stent is the 1st specifically designed for the drainage of a pancreatic pseudocyst by creating a new, temporary opening between the pancreas and the gastrointestinal tract.